Compare Biogen Inc (BIIB) vs Five Below Inc (FIVE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Five Below Inc — how do they compare? Biogen Inc trades at $204.1 (market cap $30.60B), while Five Below Inc trades at $234.71 (market cap $13.01B). The key difference: Biogen Inc is far larger — about 2.4× Five Below Inc's market cap. Which is the better fit depends on your goals.
| BIIB | FIVE | |
|---|---|---|
Market Cap | $30.60B | $13.01B |
Sector | Health | Consumer Staples |
52-Week High | $216.63 | $247.71 |
52-Week Low | $128.00 | $131.94 |
Enterprise Value | $37.67B | $13.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $207.94, up 0.8% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $234.47. The company has beaten earnings estimates for three consecutive quarters, including Q2 2026 EPS of $3.60 versus $2.94 expected, and recently completed the acquisition of RayThera Inc. to bolster its immunology pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%.
The outlook is positive, driven by strong execution and growth from newer drugs like Leqembi, though risks include pressure on legacy multiple sclerosis sales and a high P/E ratio of 36.93. The stock offers potential upside to the analyst target but faces earnings volatility and integration risks from recent acquisitions.
Five Below (FIVE) is trading at $244.37, up 5.73% with strong bullish momentum. The stock shows consistent earnings beats, with Q1 2026 EPS of $2.22 exceeding expectations of $1.77. Technical indicators signal bullish sentiment, supported by positive moving averages. Revenue growth remains solid, projected to reach $5.1B in 2026, though net margins have compressed from 9.78% in 2022 to 6.54% in 2025. Analyst consensus is strongly bullish with 62% buy ratings and a $252.36 price target.
FIVE presents a compelling growth story with expanding revenue and strong institutional support. However, elevated valuation multiples (P/E 30.79) and compressed profit margins pose risks. The stock's proximity to 52-week highs suggests limited near-term upside without significant catalysts. Execution on store expansion and margin improvement will be critical for sustained outperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Five Below Inc
Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →
